—
C+
C+ The full Closelooknet — membership. Open the C+ overview

GSK plc (GSK) — chart, structure and Closelooknet read

The Closelooknet read

GSK researches, develops and manufactures vaccines and medicines through two segments, Commercial Operations and Total R&D. It sells specialty medicines for oncology, respiratory conditions and immune disease, vaccines against shingles, meningitis, RSV and other infections, and general medicines for asthma and COPD.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for GSK, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 48/100 · S&P 500 fund at 51, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-10
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 67th percentile of the window, -18.1% over 20 sessions. Factor regime → 2026-11-10
  • Sector × region Health care in US: +2.6% week · +9.8% month · +12.6% quarter · +32.1% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-11-10
  • Sovereign pressure Index -1.67 · down 1.71 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-11-09
How it trades on rate days beta 0.96 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How GSK has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.96 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), GSK plc moved 0.96% on average · correlation 0.35 · higher than 78% of US names
  • Beta, last 3 months 1.25 more rate-sensitive lately than over the year
  • On the 10 worst bond days −0.99% on average against −0.72% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −0.60% TLT −1.32% that day 2026-11-10

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Drug Manufacturers - General · US · 8 names with week and year-to-date

Peer group

Drug Manufacturers - General · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against GSK on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — GSK plc

GSK in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
GSK researches, develops and manufactures vaccines and medicines through two segments, Commercial Operations and Total R&D. It sells specialty medicines for oncology, respiratory conditions and immune disease, vaccines against shingles, meningitis, RSV and other infections, and general medicines for asthma and COPD. It also runs partnerships, including work with CureVac on mRNA vaccines and AN2 Therapeutics on tuberculosis treatments. It is headquartered in London and was renamed from GlaxoSmithKline to GSK.
Where it sits in the stack
GSK holds no seat in our index and sits outside the layers the diary tracks for the AI build-out. It belongs to the Healthcare sector of Closelooknet's universe, classified under drug manufacturers.
Who it is priced against
Closelooknet groups it with scored healthcare names sharing its sector and country: argenx, Medpace, BeiGene, Globus Medical, Regeneron, Veeva Systems, Vertex Pharmaceuticals and Corcept Therapeutics. The market also names Pfizer as a comparable large drugmaker.
Why Closelooknet tracks it
GSK carries a Closelooknet score, with quality its strongest module and momentum its weakest. It has no index seat and no recorded quotes in the diary so far.
What the diary watches
Whether the recent broker downgrade to Sector Perform from Outperform coincides with further softening in the momentum reading already flagged as weak.

GSK plc (GSK) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 55/100 composite (momentum 54, quality 78, valuation 54) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: initiation by RBC Capital, 2026-09-08

The Street on this name

Analyst actions and the latest print for GSK from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Initiation RBC Capital — at Sector Perform Initiated to Sector Perform from Outperform 2026-09-08

1 action on the analyst wire since 2026-08-13: 1 initiation. Analyst wire → · Earnings wire →

Dividends and capital return trailing yield 3.54%, quarterly · buybacks 1.36 bn USD in FY2025

Dividends and capital return

What GSK pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 1.82 USD per share · a 3.54% yield on the 2026-11-10 close 4 distributions, paid quarterly 2026-11-10
  • Change on the year +44.4% against the prior twelve months prior twelve months 1.26 USD per share
  • Last distribution 0.45 USD per share as the price series records it, within days of the ex-date 2026-08-14
  • By calendar year 2025: 1.67 USD (partial) · 2026: 1.40 USD to date first distribution recorded in the three-year window: 2025-02-21
  • Dividends paid, FY2025 2.56 bn USD 38% of earnings
  • Buybacks, FY2025 1.36 bn USD 1.4% of today's market value
  • Share count −0.6% in FY2025 374 m USD of stock-based compensation in the year
  • Capital returned 3.93 bn USD · 61% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-11-11

Quick answers

What is GSK plc (GSK)?

GSK plc trades as GSK on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-11-11.

Is GSK in a Closelooknet index?

Not currently — GSK plc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-11-11.

What is GSK plc's Closelooknet composite score?

55 out of 100, with momentum 54, quality 78 and valuation 54 sub-scores, as of 2026-11-11. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does GSK trade against its moving averages?

GSK plc trades 3.9% above its 50-day and 1.2% below its 200-day moving average (2.5% above its 20-day). As of 2026-11-10 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does GSK plc compare with its peers?

Against its peer group (Drug Manufacturers - General · US), GSK plc (GSK) sits 14.8% below its 52-week high, 3.9% above its 50-day average; Amgen Inc (AMGN) is 3.9% below, Sanofi ADR (SNY) is 3.4% below, Gilead Sciences Inc (GILD) is 3.2% below, as of 2026-11-10. Put any of them next to GSK in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does GSK plc trade when bond yields rise?

Over the past year GSK plc had a beta of 0.96 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 78% of US names. On the 10 sessions in which long bonds fell most it moved −0.99% on average, against −0.72% for the S&P 500. As of 2026-11-10; The "How it trades on rate days" block on this page carries the lines.

What does GSK plc do?

GSK researches, develops and manufactures vaccines and medicines through two segments, Commercial Operations and Total R&D. It sells specialty medicines for oncology, respiratory conditions and immune disease, vaccines against shingles, meningitis, RSV and other infections, and general medicines for asthma and COPD. It also runs partnerships, including work with CureVac on mRNA vaccines and AN2 Therapeutics on tuberculosis treatments. Closelooknet groups it with scored healthcare names sharing its sector and country: argenx, Medpace, BeiGene, Globus Medical, Regeneron, Veeva Systems, Vertex Pharmaceuticals and Corcept Therapeutics. The market also names Pfizer as a comparable large drugmaker. (Company snapshot of 2026-09-17.)

Where does GSK plc sit in the AI build-out?

GSK holds no seat in our index and sits outside the layers the diary tracks for the AI build-out. It belongs to the Healthcare sector of Closelooknet's universe, classified under drug manufacturers. GSK carries a Closelooknet score, with quality its strongest module and momentum its weakest. It has no index seat and no recorded quotes in the diary so far. (Company snapshot of 2026-09-17.)

Does GSK plc pay a dividend?

GSK plc has paid 1.82 USD per share over the last twelve months, paid quarterly, a trailing yield of 3.54% on the 2026-11-10 close; the last distribution recorded in the price series was 0.45 USD on 2026-08-14. In fiscal 2025 the company paid 2.56 bn USD in dividends and bought back 1.36 bn USD of its own shares, 61% of that year’s free cash flow. The share count fell 0.6% over the fiscal year. As of 2026-11-10; the "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on GSK plc recently?

The most recent analyst action on GSK plc on the Closelooknet wire is a initiation by RBC Capital on 2026-09-08 (at Sector Perform). 1 action on the analyst wire since 2026-08-13: 1 initiation. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for GSK, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.